Provided by Tiger Trade Technology Pte. Ltd.

Bellicum Pharmaceuticals

0.0748
-0.0053-6.68%
Volume:6.06K
Turnover:512.03
Market Cap:726.34K
PE:-0.10
High:0.0900
Open:0.0801
Low:0.0717
Close:0.0801
52wk High:1.31
52wk Low:0.0600
Shares:9.72M
Float Shares:8.20M
Volume Ratio:1.85
T/O Rate:0.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7253
EPS(LYR):-0.8101
ROE:-148.50%
ROA:-78.10%
PB:-0.03
PE(LYR):-0.09

Loading ...

Company Profile

Company Name:
Bellicum Pharmaceuticals
Exchange:
PINK
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.